Generic GLP-1 Race Begins in India: Torrent Pharma Emerges as Early Mover, Says ICICI Securities

India’s pharmaceutical sector is set to witness intensified competition as the race to launch generic GLP-1 drugs gathers momentum, with several companies positioning themselves to tap into the fast-growing diabetes and weight-loss treatment market.

According to a report by ICICI Securities, Torrent Pharmaceuticals has emerged as an early mover by disclosing plans to launch a generic version of oral semaglutide in India. This development could give the company a first-mover advantage in a segment that is expected to see significant demand in the coming years.

GLP-1 receptor agonists, including semaglutide, are widely used for managing type 2 diabetes and obesity, with global demand rising sharply. The segment is currently dominated by innovator companies like Novo Nordisk, but Indian generic manufacturers are now stepping in to offer more affordable alternatives.

Also Read: London Police Probe Arson on Hatzola Ambulances as Antisemitic Hate Crime in Golders Green

The report noted that some generic players have already moved ahead in launching versions of these drugs, potentially accelerating market expansion in India. This shift is likely to bring down treatment costs and increase accessibility for patients, while also intensifying competition among pharmaceutical companies.

As a result, pharma stocks are expected to remain in focus, with investors closely tracking developments in the GLP-1 space. Analysts believe that early entrants could benefit from strong market positioning as regulatory approvals and product rollouts gain pace.

Overall, the emergence of generic GLP-1 drugs marks a significant phase for India’s pharma industry, blending innovation with affordability and opening up new growth opportunities in the domestic and global markets.

Also Read: Amit Shah Set to Introduce CAPF Umbrella Bill in Rajya Sabha to Unify Force Rules